Barriers Associated With Controlling LDL-C

Author(s):

Key Takeaways

Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Implementation is inconsistent due to barriers like lack of awareness and time constraints in clinical settings.
Strategies to enhance uptake include routine integration, electronic health record reminders, and education for providers and families.

Panelists discuss how multiple systemic barriers impede optimal LDL-C control, including clinical inertia, patient adherence challenges, insurance restrictions, and the removal of key quality measures.

EP: 1.Prevalence of Cardiovascular Disease

EP: 2.AHA Guidelines and Patient Mortality

EP: 3.Role of LDL-C in ASCVD

EP: 4.Pediatric Lipid Screening

EP: 5.Lp(a) in Pediatrics

EP: 6.DCRM Recommendations for Lipid Testing and LDL-C Management

EP: 7.Other Lipid Biomarkers

EP: 8.LDL-C Management in Subpopulations

EP: 9.Cost Considerations for LDL Reduction Therapies

EP: 10.Familial Hypercholesterolemia Testing

EP: 11.Role of Lp(a) in ASCVD Risk

EP: 12.Data Analysis: State of LDL-C Control in Patients With ASCVD

EP: 13.Pediatric Lipid Treatment Recommendations

EP: 14.International Lipid Expert Panel Recommendations and RACING Trial

EP: 15.SPORT Trial

EP: 16.Novel Nonstatin LLTs for Lowering LDL-C and CVD Risk

EP: 17.CLEAR-Outcomes Data: Primary Prevention With Bempedoic Acid

Now Viewing

EP: 18.Barriers Associated With Controlling LDL-C

Video content above is prompted by the following:

What are some of the barriers associated with controlling LDL-C across clinicians, patients, payers, and policy makers (eg, failure of clinicians to intensify LLT, low patient understanding and adherence to therapy, high copays, restrictive prior authorization requirements, removal of LDL-C quality measure by NCQA-HEDIS)?